Targeting EGFR/HER family: Current and challenges for the future

Speaker: Livio Trusolino

L. Trusolino points out that identification of genetic alterations in EGFR and HER2 changed the oncology practice. He sees on horizon availability of new inhibitors that target many components of HER family of receptors, including HER3 that is known to induce resistance by activation of bypass tracks. He discusses combination therapies as a way to circumvent resistance and monitoring of resistance through a liquid biopsy for detection of mutations in bloodstream.

Discussion Points

  • Current concept in EGFR/HER targeting across tumour types
  • How to capture tumour heterogeneity / Importance of dissecting tumours
  • Mechanisms of resistance
  • New strategies in EGFR/HER inhibition
  • Future directions